Hisamitsu Pharmaceutical , Nippon Shinyaku Co., Ltd. Conclude Joint Development Agreement For HFT-290 Cancer Pain Palliative Care Agent
10/19/2005 5:13:14 PM
Tokyo (JCNN) - Hisamitsu Pharmaceutical and Nippon Shinyaku (TSE: 4516) announced on April 7 that they have entered into a joint development agreement for HFT-290, a drug candidate for the treatment of cancer pain.
The two companies will conduct Phase III clinicalt trials, and co-promote the new product in Japan.